Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: cyclerion.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/20/2021 | $14.00 | Buy | Truist Securities |
| 9/24/2021 | $7.00 | Overweight | Cantor Fitzgerald |
10-Q - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
8-K - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
10-Q - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
8-K - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
10-Q - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
DEFA14A - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
DEF 14A - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
8-K - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
10-K - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
8-K - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
Truist Securities initiated coverage of Cyclerion Therapeutics with a rating of Buy and set a new price target of $14.00
Cantor Fitzgerald initiated coverage of Cyclerion Therapeutics with a rating of Overweight and set a new price target of $7.00
SC 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
SC 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
SC 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
SC 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
SC 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
SC 13D/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
SC 13G - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
SC 13D/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
SC 13D/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
SC 13D/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht, Ph.D., will continue to work closely with Cyclerion leadership as a strategic consultant and longstanding board member; steps down from CEO role – CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a biopharmaceutical company on a mission to develop treatments for serious diseases, today announced that Regina Graul, Ph.D., has joined the company as president, effective immediately. As Cyclerion's president, she will lead the organization and will work close
Positive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment Associated with Schizophrenia (CIAS) Study in Alzheimer's Disease with vascular pathology (ADv) enrollment ongoing Appointed Steven E. Hyman, M.D. to its Board of Directors CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced second quarter 2022 financial results and a business update. "The data generated from our recent
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced the appointment of Steven E. Hyman, M.D., to its Board of Directors effective July 25. Dr. Hyman will work with Cyclerion leadership to help shape the future of its research and clinical development strategy while expanding external collaborations with scientific leaders and industry partners. "We are delighted to welcome Dr. Steve Hyman to Cyclerion. Steve is a world-renowned leader in neuroscience with deep expertise leading large-scale, collaborative research program
CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, announced today the appointment of Errol De Souza, Ph.D., to its board of directors. Dr. De Souza is a seasoned R&D and business leader with broad experience - from large pharma to start ups - in the discovery and development of therapeutics for the treatment of central nervous system (CNS) disorders. Dr. De Souza is currently the executive chairman of Bionomics Limited and a member of the board of directors of Royalty Pharma and Catalyst Biosciences. Previously, Dr. De Souza founded
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Christopher Wright, M.D., Ph.D., as Chief Medical Officer. A neurologist and neuroscientist, Dr. Wright brings to AavantiBio more than 20 years of medical research and drug development experience in specialty and CNS orphan diseases, including cystic fibrosis, dementias, epilepsy, mitochondrial diseases, and sickle cell disease. An accomplished scientific and medical leader in both the academic and biopharmaceutical communities, Dr. Wright most recently served as Senior Vice President and Chief Medical Off
ANDOVER, Mass., March 24, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Stephanie Lovell to its Board of Directors and as a member of the Nominating and Corporate Governance Committee, effective March 22, 2021. Ms. Lovell brings over 30 years of healthcare executive management, legal and board experience in both the public and private sectors. Ms. Lovell is the Executive Vice President, Medicare and Chief Legal Officer for Blue Cross Blue Shield of Massachusetts, the largest private health pla
Leading experts in central nervous system (CNS) clinical development and translational sciences to advise company’s advancement of therapeutic pipeline candidates CAMBRIDGE, Mass., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced the appointment of clinical and scientific advisory boards comprised of academic leaders with expertise in CNS diseases and the development of novel therapeutics. “We are pleased to have assembled an accomplished and diverse group of advisors with expertise that spans clinical development in neurology and tr
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), today announced that Regina Graul, Ph.D., has been promoted to Chief Executive Officer, President, and member of the Board of Directors. Since Dr. Graul joined Cyclerion as President in early December 2023, she has strengthened all aspects of the company. She has been working closely with the Board of Directors to prioritize building shareholder value by reducing Cyclerion's operating costs while leading a world-class search and evaluation team, currently triaging multiple business development prospects for which Cyclerion believes it is well suited. "From the day Regina arrived at Cyclerio
– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht, Ph.D., will continue to work closely with Cyclerion leadership as a strategic consultant and longstanding board member; steps down from CEO role – CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a biopharmaceutical company on a mission to develop treatments for serious diseases, today announced that Regina Graul, Ph.D., has joined the company as president, effective immediately. As Cyclerion's president, she will lead the organization and will work close
- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders - Michael Higgins: Seasoned biopharma executive possessing business and financial acumen with CEO and extensive board experience; former entrepreneur-in-residence at Polaris Partners with a track record of launching successful companies CAMBRIDGE, Mass., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a biopharmaceutical company on a mission to develop treatments for serious diseases, today announced the appointments of Dina Katabi,
– Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment – – Tisento Developing Zagociguat in MELAS*, a Rare Primary Mitochondrial Disease with No Approved Therapies, Leveraging Extensive Preclinical and Clinical Data Generated by Cyclerion – CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) and Tisento Therapeutics, Inc. today announced the closing of the previously disclosed asset purchase agreement. Tisento is launching with an $81 million Series A financing to support its development of the Phase 2 soluble guanylate cyclase (sGC) stimulator zagociguat in MELAS and other genetic mito
CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. ("Cyclerion" or the "Company") (NASDAQ:CYCN) today announced that it has received a formal notice from The Nasdaq Stock Market (Nasdaq) stating that Cyclerion has regained compliance with the $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2), and that Cyclerion is in compliance with all applicable listing standards. On June 1, 2022, Cyclerion was notified by Nasdaq that it was not in compliance with the minimum bid price rule because its common stock failed to meet the closing bid price of $1.00 or more for 30 consecutive business days. In order to regain compliance with
CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (the "Company", "Cyclerion Therapeutics", "Cyclerion") (NASDAQ:CYCN) announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20, effective as of 5:00 p.m. Eastern Time on May 15, 2023. The reverse stock split was approved by the Company's stockholders at its annual meeting of stockholders held on May 15, 2023, with the final ratio determined by the Company's board of directors. As a result of the reverse stock split, each twenty shares of the Company's issued and outstanding common stock will be automatically combined and converted into one issued
Definitive agreement reached with new company ("NewCo") established by certain Cyclerion shareholders and new investors Cyclerion to receive $8M in cash and 10% equity in NewCo in exchange for its zagociguat and CY3018 assets Definitive agreement signing triggers previously announced $5M equity investment in Cyclerion Cyclerion CEO Peter Hecht Ph.D. to lead NewCo while continuing to serve on the Cyclerion board as one of the company's largest shareholders Biopharma executive Errol De Souza Ph.D. elected as chair of the Cyclerion board CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) today announced corporate updates and first quarter 2023
Certain Cyclerion shareholders and new investors have agreed to invest $81M to launch a new company targeting diseases of mitochondrial dysfunction Cyclerion to receive $8M in cash and 10% equity in the new company in exchange for its zagociguat and CY3018 assets Definitive agreement signing triggers previously announced $5M equity investment in Cyclerion CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) announced today that it has signed a definitive agreement with a new private company ("NewCo") to sell two of its sGC stimulator assets in exchange for cash and equity ownership. Investors in NewCo have agreed to invest $81M to develop zagocig
CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) today announced that the Board of Directors of the Company, acting solely by all of its independent and disinterested members (the "Independent Board"), has reviewed a non-binding proposal received on March 17, 2023 from an entity formed by investors that include the Company's Chief Executive Officer (CEO), to purchase the Company's zagociguat and CY3018 assets. After consultation with its legal and financial advisors, the Independent Board has concluded that the proposal merits further pursuit. Cyclerion has entered an exclusive negotiation arrangement for a limited period to allow the parties
CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments for serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to zagociguat (previously CY6463) for the treatment of mitochondrial diseases. Zagociguat is the first CNS-penetrant sGC stimulator to be developed as a symptomatic and potentially disease-modifying therapy for serious diseases that involve the CNS. In an open-label, 29-day study in patients with MELAS*, zagociguat treatment was associated with improvements in multiple disease-relevant biomar
4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
3 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
3 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
3 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
3/A - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
3 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
Shares of ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) fell sharply during Wednesday's session after the company announced that its Singapore-incorporated, sole operating subsidiary has filed for voluntary liquidation. ASLAN Pharmaceuticals shares dipped 38.7% to $0.68 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Aptevo Therapeutics Inc. (NASDAQ:APVO) shares climbed 84% to $0.6073 after surging around 10% on Tuesday. Aptevo Therapeutics recently announced closing of $2.75 million offering. Shimmick Corporation (NASDAQ:SHIM) shares climbed 49% to $3.0173 after the company received a $27.6 million subcontract for the Sunol Valley Water Trea
Gainers DermTech (NASDAQ:DMTK) stock rose 56.6% to $0.18 during Friday's pre-market session. The market value of their outstanding shares is at $6.4 million. Sarepta Therapeutics (NASDAQ:SRPT) shares rose 39.26% to $171.99. The market value of their outstanding shares is at $16.2 billion. Kintara Therapeutics (NASDAQ:KTRA) shares increased by 17.78% to $0.32. The market value of their outstanding shares is at $17.9 million. Solid Biosciences (NASDAQ:SLDB) stock moved upwards by 17.3% to $7.39. The market value of their outstanding shares is at $283.6 million. ASLAN Pharma (NASDAQ:ASLN) stock rose 14.06% to $0.36. The market value of their outstanding shares is at $8.2 million. Alaunos
Gainers Tempest Therapeutics (NASDAQ:TPST) shares rose 32.8% to $3.79 during Thursday's pre-market session. The company's market cap stands at $84.0 million. Neurogene (NASDAQ:NGNE) shares rose 31.92% to $40.0. The company's market cap stands at $519.2 million. Geovax Labs (NASDAQ:GOVX) shares rose 28.94% to $2.45. The company's market cap stands at $6.1 million. SAB Biotherapeutics (NASDAQ:SABS) stock moved upwards by 24.03% to $3.2. The market value of their outstanding shares is at $29.5 million. Trevena (NASDAQ:TRVN) stock rose 23.33% to $0.44. The market value of their outstanding shares is at $8.0 million. Molecular Partners (NASDAQ:MOLN) stock rose 22.23% to $9.73. The company's
Gainers Cyclerion Therapeutics (NASDAQ:CYCN) shares moved upwards by 37.4% to $2.9 during Friday's regular session. The market value of their outstanding shares is at $7.2 million. CNS Pharma (NASDAQ:CNSP) stock rose 35.86% to $4.92. The market value of their outstanding shares is at $1.9 million. Longeveron (NASDAQ:LGVN) shares moved upwards by 23.23% to $3.31. The market value of their outstanding shares is at $21.0 million. iSpecimen (NASDAQ:ISPC) stock moved upwards by 19.44% to $0.49. The market value of their outstanding shares is at $4.8 million. Scinai Immunotherapeutics (NASDAQ:SCNI) stock rose 17.8% to $3.32. The market value of their outstanding shares is at $1.9 million. Di
Gainers Longeveron (NASDAQ:LGVN) stock increased by 74.6% to $3.16 during Thursday's regular session. The company's market cap stands at $20.0 million. BioRestorative Therapies (NASDAQ:BRTX) stock rose 27.4% to $1.72. The market value of their outstanding shares is at $11.6 million. Aethlon Medical (NASDAQ:AEMD) shares rose 26.84% to $0.66. The market value of their outstanding shares is at $3.3 million. Sharps Technology (NASDAQ:STSS) stock moved upwards by 23.58% to $0.37. The company's market cap stands at $6.5 million. Biomea Fusion (NASDAQ:BMEA) stock moved upwards by 20.95% to $5.6. The market value of their outstanding shares is at $201.2 million. iSpecimen (NASDAQ:ISPC) shares
Gainers Longeveron (NASDAQ:LGVN) shares rose 112.1% to $1.74 during Wednesday's regular session. The market value of their outstanding shares is at $11.0 million. vTv Therapeutics (NASDAQ:VTVT) stock increased by 43.09% to $26.0. The market value of their outstanding shares is at $63.2 million. Avidity Biosciences (NASDAQ:RNA) shares increased by 32.32% to $38.27. The company's market cap stands at $3.6 billion. Cyclerion Therapeutics (NASDAQ:CYCN) stock rose 30.39% to $2.96. The company's market cap stands at $7.3 million. Telesis Bio (NASDAQ:TBIO) stock moved upwards by 22.53% to $3.86. The company's market cap stands at $6.4 million. Autonomix Medical (NASDAQ:AMIX) stock rose 20.94%
Gainers IGM Biosciences (NASDAQ:IGMS) shares increased by 36.6% to $11.49 during Wednesday's regular session. The market value of their outstanding shares is at $678.1 million. Akso Health Group (NASDAQ:AHG) stock moved upwards by 21.96% to $1.05. The company's market cap stands at $153.8 million. MultiPlan (NYSE:MPLN) shares rose 18.57% to $0.64. The company's market cap stands at $415.4 million. Cyclerion Therapeutics (NASDAQ:CYCN) shares rose 14.61% to $2.98. The company's market cap stands at $7.4 million. TransCode Therapeutics (NASDAQ:RNAZ) shares increased by 12.79% to $1.41. The company's market cap stands at $9.3 million. Indaptus Therapeutics (NASDAQ:INDP) shares moved upward
Gainers InVivo Therapeutics Hldg (NASDAQ:NVIV) stock rose 306.0% to $0.9 during Tuesday's regular session. The company's market cap stands at $2.7 million. Cyclerion Therapeutics (NASDAQ:CYCN) stock rose 56.02% to $4.4. The company's market cap stands at $10.7 million. Tenax Therapeutics (NASDAQ:TENX) stock increased by 41.62% to $12.35. The market value of their outstanding shares is at $3.6 million. Equillium (NASDAQ:EQ) stock increased by 35.62% to $1.08. The company's market cap stands at $38.1 million. Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 31.11% to $1.77. The market value of their outstanding shares is at $202.7 million. Immunome (NASDAQ:IMNM) stock increas
Gainers Atreca (NASDAQ:BCEL) shares increased by 102.7% to $0.22 during Thursday's regular session. The company's market cap stands at $8.6 million. Sagimet Biosciences (NASDAQ:SGMT) stock rose 36.13% to $7.12. The company's market cap stands at $163.0 million. Cyclerion Therapeutics (NASDAQ:CYCN) shares increased by 19.89% to $4.4. The market value of their outstanding shares is at $10.7 million. Galera Therapeutics (NASDAQ:GRTX) stock moved upwards by 14.48% to $0.22. The market value of their outstanding shares is at $12.0 million. Sera Prognostics (NASDAQ:SERA) stock rose 14.45% to $5.78. The company's market cap stands at $181.1 million. Cyclacel Pharmaceuticals (NASDAQ:CYCCP) sha